SHANXI C&Y PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings
SHANXI C&Y PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, production, and commercialization of chemical drug substances and finished formulations. The company’s product pipeline encompasses diverse therapeutic areas, including cardiovascular health, metabolic disorders, and infectious diseases. Its manufacturing capabilities cover active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and various dosage forms such as tablets, capsules, and small-volume injections. By integrating advanced synthesis technologies with stringent quality control protocols, the group provides high-purity chemical components and effective medicinal products. The organization focuses on scaling production efficiency and expanding its portfolio of generic and innovative drugs to serve healthcare providers and patients globally.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 董事会秘书工作制度（2026年5月） | 2026-05-19 | Chinese | |
| 国浩律师（上海）事务所关于山西仟源医药集团股份有限公司2025年年度股东会之法律意见书 | 2026-05-19 | Chinese | |
| 关于向2025年限制性股票激励计划激励对象授予预留限制性股票的公告 | 2026-05-19 | Chinese | |
| 2025年年度股东会决议公告 | 2026-05-19 | Chinese | |
| 薪酬与考核委员会关于2025年限制性股票激励计划预留授予激励对象名单（预留授予日）的核查意见 | 2026-05-19 | Chinese | |
| 关于回购注销限制性股票减少注册资本暨通知债权人的公告 | 2026-05-19 | Chinese |
Browse filings by year
16 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46532251 | 董事会秘书工作制度（2026年5月） | 2026-05-19 | Chinese | ||
| 46532250 | 国浩律师（上海）事务所关于山西仟源医药集团股份有限公司2025年年度股东会之法律意见书 | 2026-05-19 | Chinese | ||
| 46532242 | 关于向2025年限制性股票激励计划激励对象授予预留限制性股票的公告 | 2026-05-19 | Chinese | ||
| 46532267 | 2025年年度股东会决议公告 | 2026-05-19 | Chinese | ||
| 46532263 | 薪酬与考核委员会关于2025年限制性股票激励计划预留授予激励对象名单（预留授予日）的核查意见 | 2026-05-19 | Chinese | ||
| 46532262 | 关于回购注销限制性股票减少注册资本暨通知债权人的公告 | 2026-05-19 | Chinese | ||
| 46532259 | 2025年限制性股票激励计划预留授予激励对象名单（预留授予日） | 2026-05-19 | Chinese | ||
| 46532269 | 国浩律师（上海）事务所关于山西仟源医药集团股份有限公司2025年限制性股票激励计划预留部分授予相关事项之法律意见书 | 2026-05-19 | Chinese | ||
| 46532281 | 第六届董事会第五次会议决议公告 | 2026-05-19 | Chinese | ||
| 46350677 | 关于召开2025年年度股东会的提示性公告 | 2026-05-15 | Chinese | ||
| 46350680 | 关于参加2026年山西辖区上市公司投资者网上集体接待日活动暨取消公司2025年度网上业绩说明会的公告 | 2026-05-15 | Chinese | ||
| 36459965 | 独立董事提名人声明与承诺（武进锋） | 2026-01-13 | Chinese | ||
| 36459960 | 第五届董事会第三十六次会议决议公告 | 2026-01-13 | Chinese | ||
| 36459949 | 关于与关联方等共同向子公司增资暨关联交易的公告 | 2026-01-13 | Chinese | ||
| 36459938 | 关于变更注册资本、修订《公司章程》并办理工商变更登记的公告 | 2026-01-13 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
SHANXI C&Y PHARMACEUTICAL GROUP CO.,LTD via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55260/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55260 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55260 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55260 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55260}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for SHANXI C&Y PHARMACEUTICAL GROUP CO.,LTD (id: 55260)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.